Document is current
Any future updates will be listed below
-
Authors
Johnson, Richard J. https://orcid.org/0000-0003-3312-8193
Lanaspa, Miguel A. https://orcid.org/0000-0002-1163-1831
Tolan, Dean R.
Goncalves, Marcus D. https://orcid.org/0000-0002-0784-9248
Softic, Samir https://orcid.org/0000-0003-1419-9789
Stanhope, Kimber L.
Sánchez-Lozada, Laura G.
Herman, Mark A. https://orcid.org/0000-0001-6979-103X
Rabinowitz, Joshua D. https://orcid.org/0000-0002-1247-4727
- License Information
-
More Information
Article History
Received: 30 April 2025
Accepted: 6 March 2026
First Online: 17 April 2026
Competing interests
: R.J.J., M.A.L., D.R.T. and J.D.R. have equity with Colorado Research Partners, which is developing KHK inhibitors. R.J.J. also consults for Amgen, Dynamicure, Soba Pharmaceuticals and Kibow and is on the Scientific Board of Blue Oak Nutraceuticals, Santa Barbara Nutrients and RxSugar. M.D.G. holds equity in Faeth Therapeutics and Skye Biosciences; reports consulting or advisory roles with Almac Discovery, Genentech, Faeth Therapeutics, Scorpion Therapeutics and Skye Biosciences; patents, royalties and other intellectual property with Weill Cornell Medicine and Faeth Therapeutics. J.D.R. is a member of the Rutgers Cancer Institute (RCI) and the University of Pennsylvania Diabetes Research Center (U Penn DRC); director of the U Penn DRC-Princeton inter-institutional metabolomics core and RCI metabolomics core; advisor and stockholder in Bantam Pharmaceuticals, Rafael Pharmaceuticals and Empress Therapeutics; a founder, director and stockholder of Farber Partners and Raze Therapeutics; a founder, advisor and stockholder in Marea Therapeutics and Fargo Biotechnologies; and inventor of patents held by Princeton University. S.S., K.L.S., L.G.S-L. and M.A.H. declare no competing interests.
